Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: Monoclonal antibodies are a treatment option for patients with mild-to-moderate coronavirus disease (COVID-19). We investigated the effectiveness of regdanvimab, an anti-severe acute respiratory syndrome coronavirus-2 monoclonal antibody approved in Korea, in the treatment of patients with mild-to-moderate COVID-19. Materials and methods: Medical records of patients who were admitted to a COVID-19 designated hospital during the study period of February 1 to June 31 and met the indications for administration of regdanvimab were reviewed to assess baseline characteristics and clinical outcomes such as supplemental oxygen requirements, mortality, and length of hospitalization. Multivariable logistic regression analysis was conducted to identify factors associated with requiring supplemental oxygen. Subgroup analysis was performed according to the presence of pneumonia confirmed on a chest X-ray. Results: Three hundred ninety-eight COVID-19 patients were included in the study, and 65 (16.3%) of them were administered regdanvimab. The proportion of patients requiring supplemental oxygen was significantly lower in the regdanvimab group than in the control group (6.2% vs. 20.1%, P = 0.007). There was no significant difference in mortality (0% vs. 1.5%, P >0.999) and the length of hospitalization (median: 10 days vs. 10 days, P = 0.267) between two groups. The multivariable analysis demonstrated that administration of regdanvimab was independently associated with lower oxygen supplement [odds ratio (OR): 0.20, 95% confidence interval (CI): 0.06 - 0.55, P = 0.004] after adjustment of potential risk factors related to supplemental oxygen including age, sex, chest X-ray abnormality, and underlying chronic kidney disease. Among the patients with pneumonia radiologically, administration of regdanvimab was also associated with lower risk of oxygen supplement (OR: 0.13, 95% CI: 0.02 - 0.46, P = 0.007). Conclusion: Regdanvimab use was related to lower need for supplemental oxygen in patients with mild-to-moderate COVID-19 for the indications for administration of regdanvimab.
Abstract
Background: Monoclonal antibodies are a treatment option for patients with mild-to-moderate coronavirus disease (COVID-19). We investigated the effectiveness of regdanvimab, an anti-severe acute respiratory syndrome coronavirus-2 monoclonal antibody approved in Korea, in the treatment of patients with mild-to-moderate COVID-19. Materials and methods: Medical records of patients who were admitted to a COVID-19 designated hospital during the study period of February 1 to June 31 and met the indications for administration of regdanvimab were reviewed to assess baseline characteristics and clinical outcomes such as supplemental oxygen requirements, mortality, and length of hospitalization. Multivariable logistic regression analysis was conducted to identify factors associated with requiring supplemental oxygen. Subgroup analysis was performed according to the presence of pneumonia confirmed on a chest X-ray. Results: Three hundred ninety-eight COVID-19 patients were included in the study, and 65 (16.3%) of them were administered regdanvimab. The proportion of patients requiring supplemental oxygen was significantly lower in the regdanvimab group than in the control group (6.2% vs. 20.1%, P = 0.007). There was no significant difference in mortality (0% vs. 1.5%, P >0.999) and the length of hospitalization (median: 10 days vs. 10 days, P = 0.267) between two groups. The multivariable analysis demonstrated that administration of regdanvimab was independently associated with lower oxygen supplement [odds ratio (OR): 0.20, 95% confidence interval (CI): 0.06 - 0.55, P = 0.004] after adjustment of potential risk factors related to supplemental oxygen including age, sex, chest X-ray abnormality, and underlying chronic kidney disease. Among the patients with pneumonia radiologically, administration of regdanvimab was also associated with lower risk of oxygen supplement (OR: 0.13, 95% CI: 0.02 - 0.46, P = 0.007). Conclusion: Regdanvimab use was related to lower need for supplemental oxygen in patients with mild-to-moderate COVID-19 for the indications for administration of regdanvimab.
참고문헌 (29)
- Wu F, "A new coronavirus associated with human respiratory disease in China", Nature, 579, pp.265~269 (2020)
- Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- "Therapeutics and covid-19: living guideline"[URL]
- Dougan M, "Bamlanivimab plus Etesevimab in mild or moderate Covid-19", N Engl J Med, 385, pp.1382~1392 (2021)
- "COVID-19 treatment guidelines"[URL]
- Gupta A, "Early treatment for Covid-19 with SARSCoV-2 neutralizing antibody Sotrovimab", N Engl J Med, 385, pp.1941~1950 (2021)
- Weinreich DM, "REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19", N Engl J Med, 384, pp.238~251 (2021)
- Weinreich DM, "REGEN-COV antibody combination and outcomes in outpatients with Covid-19", N Engl J Med, 385, pp.e81~ (2021)
- Eom JS, "Efficacy and safety of ct-p59 plus standard of care: A phase 2", 3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection, 2021, ~
- Kim Shin-Woo, "Clinical Characteristics and Outcomes of COVID-19 Cohort Patients in Daegu Metropolitan City Outbreak in 2020", Journal of Korean Medical Science, 36(1), pp.1~15 (2021), 대한의학회[DOI]
- CDC COVID-19 Response Team, "Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12-March 28, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.382~386 (2020)
- Gansevoort RT, "CKD is a key risk factor for COVID-19 mortality", Nat Rev Nephrol, 16, pp.705~706 (2020)
- Cai Q, "Obesity and COVID-19 severity in a designated hospital in Shenzhen, China", Diabetes Care, 43, pp.1392~1398 (2020)
- Lee Sun Young, "Operation and Management of Seoul Metropolitan City Community Treatment Center for Mild Condition COVID-19 Patients", Journal of Korean Medical Science, 35(40), pp.1~13 (2020), 대한의학회[DOI]
- Lee JY, "Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease", Front Immunol, 12, pp.772320~ (2021)
- Kim IH, "July 2021status and characteristics of the covid-19 variant virus outbreak in the Republic of Korea", Public Healthy Weekly Report, 14, pp.2555~2560 (2021)
- Cherian S, "SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India", Microorganisms, 9, pp.1542~ (2021)
- Liu L, "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2", Nature, 602, pp.676~681 (2022)
- Planas D, "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization", Nature, 596, pp.276~280 (2021)
- Cele S, "Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization", Nature, 602, pp.654~656 (2022)
- Planas D, "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization", Nature, 602, pp.671~675 (2022)
- Kim C, "A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein", Nat Commun, 12, pp.288~ (2021)
- Barnes CO, "SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies", Nature, 588, pp.682~687 (2020)
- Ryu DK, "The in vitro and in vivo potency of ct-p59against delta and its associated variants of SARS-CoV-2", bioRxiv, ~ (2021)
- VanBlargan LA, "An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies", Nat Med, pp.1~6 (2022)